Matches in SemOpenAlex for { <https://semopenalex.org/work/W3017313048> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W3017313048 endingPage "SP321" @default.
- W3017313048 startingPage "SP315" @default.
- W3017313048 abstract "To evaluate adherence to newly initiated biologic disease-modifying antirheumatic drugs (bDMARDs) in effectively treated patients with rheumatoid arthritis (RA).Retrospective cohort study of administrative claims data (IMS PharMetrics Plus) for services incurred from July 1, 2008, to December 31, 2014.Data from patients with RA aged 18 to 64 years with continuous enrollment for at least 30 months and initiating abatacept, adalimumab, certolizumab pegol, etanercept, golimumab, or infliximab were analyzed. Treatment effectiveness was determined using a validated algorithm. Outcomes included adherence rates (proportion of days covered ≥80%) for 1 year and 2 years, year 2 adherence among patients effectively and noneffectively treated in year 1, year 2 adherence predictors, and year 2 costs and cost predictors.Across 10,374 patients, adherence rates were 46% for year 1 and 34% for 2 years; rates were lowest for golimumab and highest for infliximab. In year 1, 3076 (29.7%) patients were considered effectively treated. Year 2 adherence was 59% in effectively treated patients, 32% in patients who failed any effectiveness criteria, and 12% in patients who failed only the adherence criterion. Intravenous bDMARDs, older age, male sex, Northeast region, commercial payer, prior DMARD use, index year 2010 or later, and lower preindex all-cause costs each predicted better adherence. Adjusted year 2 all-cause and RA-related costs were $39,425 and $22,123, respectively, for effectively treated patients and $25,313 and $9250 for noneffectively treated patients. Cost predictors included effective treatment, region, payer, and index year.Adherence to the first bDMARD was suboptimal even in effectively treated patients, suggesting opportunities to improve adherence in patients with RA initiating biologics." @default.
- W3017313048 created "2020-04-24" @default.
- W3017313048 creator A5034329124 @default.
- W3017313048 creator A5034570687 @default.
- W3017313048 creator A5054726198 @default.
- W3017313048 creator A5058483219 @default.
- W3017313048 creator A5063676674 @default.
- W3017313048 creator A5091055016 @default.
- W3017313048 date "2018-07-01" @default.
- W3017313048 modified "2023-09-27" @default.
- W3017313048 title "Two-year adherence and costs for biologic therapy for rheumatoid arthritis." @default.
- W3017313048 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30020744" @default.
- W3017313048 hasPublicationYear "2018" @default.
- W3017313048 type Work @default.
- W3017313048 sameAs 3017313048 @default.
- W3017313048 citedByCount "4" @default.
- W3017313048 countsByYear W30173130482019 @default.
- W3017313048 countsByYear W30173130482022 @default.
- W3017313048 crossrefType "journal-article" @default.
- W3017313048 hasAuthorship W3017313048A5034329124 @default.
- W3017313048 hasAuthorship W3017313048A5034570687 @default.
- W3017313048 hasAuthorship W3017313048A5054726198 @default.
- W3017313048 hasAuthorship W3017313048A5058483219 @default.
- W3017313048 hasAuthorship W3017313048A5063676674 @default.
- W3017313048 hasAuthorship W3017313048A5091055016 @default.
- W3017313048 hasConcept C126322002 @default.
- W3017313048 hasConcept C167135981 @default.
- W3017313048 hasConcept C1862650 @default.
- W3017313048 hasConcept C2776215756 @default.
- W3017313048 hasConcept C2777138892 @default.
- W3017313048 hasConcept C2777226972 @default.
- W3017313048 hasConcept C2777575956 @default.
- W3017313048 hasConcept C2779134260 @default.
- W3017313048 hasConcept C2779338263 @default.
- W3017313048 hasConcept C2779605438 @default.
- W3017313048 hasConcept C2780132546 @default.
- W3017313048 hasConcept C2780653079 @default.
- W3017313048 hasConcept C2781290027 @default.
- W3017313048 hasConcept C71924100 @default.
- W3017313048 hasConceptScore W3017313048C126322002 @default.
- W3017313048 hasConceptScore W3017313048C167135981 @default.
- W3017313048 hasConceptScore W3017313048C1862650 @default.
- W3017313048 hasConceptScore W3017313048C2776215756 @default.
- W3017313048 hasConceptScore W3017313048C2777138892 @default.
- W3017313048 hasConceptScore W3017313048C2777226972 @default.
- W3017313048 hasConceptScore W3017313048C2777575956 @default.
- W3017313048 hasConceptScore W3017313048C2779134260 @default.
- W3017313048 hasConceptScore W3017313048C2779338263 @default.
- W3017313048 hasConceptScore W3017313048C2779605438 @default.
- W3017313048 hasConceptScore W3017313048C2780132546 @default.
- W3017313048 hasConceptScore W3017313048C2780653079 @default.
- W3017313048 hasConceptScore W3017313048C2781290027 @default.
- W3017313048 hasConceptScore W3017313048C71924100 @default.
- W3017313048 hasIssue "8 Spec No." @default.
- W3017313048 hasLocation W30173130481 @default.
- W3017313048 hasOpenAccess W3017313048 @default.
- W3017313048 hasPrimaryLocation W30173130481 @default.
- W3017313048 hasRelatedWork W108172154 @default.
- W3017313048 hasRelatedWork W1980351720 @default.
- W3017313048 hasRelatedWork W2057389856 @default.
- W3017313048 hasRelatedWork W2125169255 @default.
- W3017313048 hasRelatedWork W2324541994 @default.
- W3017313048 hasRelatedWork W2734364973 @default.
- W3017313048 hasRelatedWork W2807782139 @default.
- W3017313048 hasRelatedWork W2948813200 @default.
- W3017313048 hasRelatedWork W3044415029 @default.
- W3017313048 hasRelatedWork W4238923943 @default.
- W3017313048 hasVolume "24" @default.
- W3017313048 isParatext "false" @default.
- W3017313048 isRetracted "false" @default.
- W3017313048 magId "3017313048" @default.
- W3017313048 workType "article" @default.